Search / Trial NCT00000244

Effects of Dynorphin 1-13 on Heroin Addiction - 1

Launched by UNIVERSITY OF MINNESOTA · Sep 20, 1999

Trial Information

Current as of December 09, 2024

Completed

Keywords

Addiction Opiate Heroin Dynorphin

ClinConnect Summary

Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • opiate addict between the ages of 18-55
  • Exclusion Criteria:
  • Regular abuse of other drugs, unstable medical conditions

Trial Officials

Paul Pentel, M.D.

Principal Investigator

University of Minnesota

About University Of Minnesota

The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.

Locations

Minneapolis, Minnesota, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials